Loading clinical trials...
Loading clinical trials...
HFHS-1801-A Pilot Study of Immunotherapy As Consolidation Therapy for Patients with Recurrent Head and Neck Cancer High Risk Pathologic Features Following Surgical Salvage and Are Not Eligible for Post-operative Radiation Therapy
Conditions
Interventions
Pembrolizumab 25 MG/1 ML Intravenous Solution [KEYTRUDA]
Locations
1
United States
Henry Ford Health System
Detroit, Michigan, United States
Start Date
October 4, 2019
Primary Completion Date
June 15, 2023
Completion Date
May 8, 2024
Last Updated
December 4, 2024
NCT06998069
NCT06912087
NCT06303180
NCT07158164
NCT04429542
NCT05811936
Lead Sponsor
Henry Ford Health System
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions